Immune reconstitution at 12 months can predict superior overall survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML ; a single centre experience

Kanellopoulos, A.; Saeed, M.; Kaparou, M.; Eden, D.; Khawaja, J.; Cain, L.; Qureshi, I.; Xenou, E.; Lee, S.; Randall, K.; Arbuthnot, C.; Borg, A.; Holder, K.; Bratby, L.; Kishore, B.; Lovell, R.; Paneesha, S.; Nikolousis, E.

Affiliation

Heart of England NHS Trust; New Cross Hospital, Wolverhampton; South Warwickshire University NHS Foundation Trust

Publication date

2016-03-21

Subject

Transplantation
Haematology

Metadata

Show full item record

Abstract

Physicians Poster Sessions abstract P245 of the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, Valencia, Spain, 3–6 April 2016.

Citation

Kanellopoulos A, Saeed M, Kaparou M, Eden D, Khawaja J, Cain L, Qureshi I, Xenou E, Lee S, Randall K, Arbuthnot C, Borg A, Holder K, Bratby L, Kishore B, Lovell R, Paneesha S, Nikolousis E. Immune reconstitution at 12 months can predict superior overall survival in reduced intensity alemtuzumab based conditioning transplant recipients for high risk MDS and AML; a single centre experience. Bone Marrow Transplant. 2016 Mar;51(Suppl 1):S242. doi: 10.1038/bmt.2016.48.

Type

Conference Output